Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	588.99	491.73	398.2	214.2	140.83
Revenue Growth (YoY)	19.78%	23.49%	85.90%	52.10%	18.27%
Cost of Revenue	87.25	68.85	51.97	34.39	21.88
Gross Profit	501.74	422.89	346.24	179.81	118.95
Selling, General & Admin	193.75	177.74	133.71	57.09	49.63
Depreciation & Amortization Expenses	37.5	37.38	32.57	1.1	-
Research & Development	12.71	12.65	93.15	19.79	16.94
Total Operating Expenses	243.96	227.77	259.43	77.97	66.56
Operating Income	257.78	195.12	86.81	101.84	52.39
Total Non-Operating Income (Expense)	25.74	21.14	7.7	2.88	0.28
Pretax Income	283.52	216.26	94.51	104.72	52.67
Provision for Income Taxes	69.19	52.37	23.1	21.64	13.19
Net Income	214.33	163.89	71.41	83.08	39.48
Net Income to Common	214.33	163.89	71.41	83.08	39.48
Net Income Growth	30.78%	129.50%	-14.05%	110.42%	-47.34%
Shares Outstanding (Basic)	122	118	106	103	103
Shares Outstanding (Diluted)	127	125	114	111	108
Shares Change (YoY)	1.85%	9.84%	2.14%	3.32%	1.46%
EPS (Basic)	1.75	1.38	0.67	0.80	0.38
EPS (Diluted)	1.68	1.31	0.63	0.75	0.37
EPS Growth	28.24%	107.94%	-16.00%	102.70%	-47.89%
Free Cash Flow	208.61	239.25	143.37	116.02	59.35
Free Cash Flow Growth	-12.81%	66.88%	23.57%	95.48%	31.82%
Free Cash Flow Per Share	1.64	1.91	1.26	1.04	0.55
Gross Margin	85.19%	86.00%	86.95%	83.94%	84.46%
Operating Margin	43.77%	39.68%	21.80%	47.54%	37.20%
Profit Margin	36.39%	33.33%	17.93%	38.79%	28.03%
FCF Margin	35.42%	48.65%	36.00%	54.16%	42.14%
EBITDA	295.65	232.9	119.69	103.08	52.58
EBITDA Margin	50.20%	47.36%	30.06%	48.12%	37.33%
EBIT	257.78	195.12	86.81	101.84	52.39
EBIT Margin	43.77%	39.68%	21.80%	47.54%	37.20%
Effective Tax Rate	24.40%	24.22%	24.44%	20.66%	25.03%

Updated Feb 25, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q